JP2016536012A5 - - Google Patents

Download PDF

Info

Publication number
JP2016536012A5
JP2016536012A5 JP2016549206A JP2016549206A JP2016536012A5 JP 2016536012 A5 JP2016536012 A5 JP 2016536012A5 JP 2016549206 A JP2016549206 A JP 2016549206A JP 2016549206 A JP2016549206 A JP 2016549206A JP 2016536012 A5 JP2016536012 A5 JP 2016536012A5
Authority
JP
Japan
Prior art keywords
pkal
inhibitor
assay
subject
plasma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016549206A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016536012A (ja
JP6757252B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/061247 external-priority patent/WO2015061183A1/en
Publication of JP2016536012A publication Critical patent/JP2016536012A/ja
Publication of JP2016536012A5 publication Critical patent/JP2016536012A5/ja
Application granted granted Critical
Publication of JP6757252B2 publication Critical patent/JP6757252B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016549206A 2013-10-21 2014-10-17 血漿カリクレイン系バイオマーカーを決定するためのアッセイ Active JP6757252B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361893505P 2013-10-21 2013-10-21
US61/893,505 2013-10-21
US201461939837P 2014-02-14 2014-02-14
US61/939,837 2014-02-14
PCT/US2014/061247 WO2015061183A1 (en) 2013-10-21 2014-10-17 Assays for determining plasma kallikrein system biomarkers

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020144118A Division JP7135039B2 (ja) 2013-10-21 2020-08-28 血漿カリクレイン系バイオマーカーを決定するためのアッセイ

Publications (3)

Publication Number Publication Date
JP2016536012A JP2016536012A (ja) 2016-11-24
JP2016536012A5 true JP2016536012A5 (cg-RX-API-DMAC7.html) 2017-11-24
JP6757252B2 JP6757252B2 (ja) 2020-09-16

Family

ID=52993413

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2016549206A Active JP6757252B2 (ja) 2013-10-21 2014-10-17 血漿カリクレイン系バイオマーカーを決定するためのアッセイ
JP2020144118A Active JP7135039B2 (ja) 2013-10-21 2020-08-28 血漿カリクレイン系バイオマーカーを決定するためのアッセイ
JP2022137393A Active JP7668772B2 (ja) 2013-10-21 2022-08-31 血漿カリクレイン系バイオマーカーを決定するためのアッセイ
JP2024117419A Pending JP2024150637A (ja) 2013-10-21 2024-07-23 血漿カリクレイン系バイオマーカーを決定するためのアッセイ

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2020144118A Active JP7135039B2 (ja) 2013-10-21 2020-08-28 血漿カリクレイン系バイオマーカーを決定するためのアッセイ
JP2022137393A Active JP7668772B2 (ja) 2013-10-21 2022-08-31 血漿カリクレイン系バイオマーカーを決定するためのアッセイ
JP2024117419A Pending JP2024150637A (ja) 2013-10-21 2024-07-23 血漿カリクレイン系バイオマーカーを決定するためのアッセイ

Country Status (13)

Country Link
US (2) US11372002B2 (cg-RX-API-DMAC7.html)
EP (2) EP3808857B1 (cg-RX-API-DMAC7.html)
JP (4) JP6757252B2 (cg-RX-API-DMAC7.html)
KR (4) KR102521947B1 (cg-RX-API-DMAC7.html)
CN (1) CN105873951A (cg-RX-API-DMAC7.html)
AU (3) AU2014340450B2 (cg-RX-API-DMAC7.html)
BR (1) BR112016008970B1 (cg-RX-API-DMAC7.html)
CA (1) CA2927824C (cg-RX-API-DMAC7.html)
DK (1) DK3060582T3 (cg-RX-API-DMAC7.html)
ES (1) ES2837858T3 (cg-RX-API-DMAC7.html)
IL (3) IL289514B2 (cg-RX-API-DMAC7.html)
PL (1) PL3060582T3 (cg-RX-API-DMAC7.html)
WO (1) WO2015061183A1 (cg-RX-API-DMAC7.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3459564T1 (sl) 2010-01-06 2022-06-30 Takeda Pharmaceutical Company Limited Proteini, ki vežejo plazemski kalikrein
JP2014506257A (ja) * 2011-01-06 2014-03-13 ダイアックス コーポレーション 血漿カリクレイン結合タンパク質
EP3456744B1 (en) * 2013-01-20 2023-03-29 Takeda Pharmaceutical Company Limited Evaluation and treatment of bradykinin-mediated disorders
AU2014340450B2 (en) 2013-10-21 2020-05-21 Takeda Pharmaceutical Company Limited Assays for determining plasma kallikrein system biomarkers
US10101344B2 (en) 2013-10-21 2018-10-16 Dyax Corp. Diagnosis and treatment of autoimmune diseases
EA038532B1 (ru) 2014-01-21 2021-09-10 Такеда Фармасьютикал Компани Лимитед Способ лечения наследственного ангионевротического отека (hae)
IL295414B1 (en) 2014-03-27 2025-10-01 Takeda Pharmaceuticals Co Compositions and methods for treating macular edema due to diabetes
EP3286226A4 (en) * 2015-03-30 2018-12-05 Dyax Corp. Plasma kallikrein inhibitors and uses thereof for preventing hereditary angioedema attack
EP3334343B1 (en) * 2015-08-13 2022-10-19 Takeda Pharmaceutical Company Limited Evacuated blood collection tubes containing protease inhibitors for the assessment of contact system activation
PL3365685T3 (pl) * 2015-10-19 2021-08-02 Dyax Corp. Test immunologiczny do wykrywania rozszczepionego wielkocząsteczkowego kininogenu
AU2016372159B2 (en) 2015-12-15 2022-03-24 Takeda Pharmaceutical Company Limited Peptide quantitation assay for differentiating full-length high molecular weight kininogen (HMWK) and cleaved HMWK
IL265195B2 (en) * 2016-09-16 2025-02-01 Dyax Corp Protein biomarkers for diseases related to the activation system
IL315175A (en) * 2016-09-16 2024-10-01 Takeda Pharmaceuticals Co RNA biomarkers for hereditary angioedema
BR112019005167A2 (pt) * 2016-09-16 2019-07-02 Dyax Corp. método e kit para analisar uma amostra
EP3521828A1 (en) * 2018-01-31 2019-08-07 Centogene AG Method for the diagnosis of hereditary angioedema
WO2019165308A1 (en) * 2018-02-22 2019-08-29 The Regents Of The University Of California Threshold-stimulated plasma kallikrein activity as a biomarker for diagnosis of bradykinin-mediated angioedema
CN111057745B (zh) * 2019-12-30 2022-08-12 中国科学院生态环境研究中心 一种物质的血液毒性效应的高通量筛选方法
CN113777331A (zh) * 2020-06-09 2021-12-10 张曼 尿液激肽原-1及其多肽片段在烧伤中的应用
CN114166924B (zh) * 2021-12-03 2024-11-22 中国医学科学院北京协和医院 尿液蛋白标志物在诊断遗传性血管水肿中的用途
JP2025522757A (ja) * 2022-06-30 2025-07-17 武田薬品工業株式会社 ラナデルマブ治療のためのタンパク質バイオマーカー
WO2025153806A1 (en) * 2024-01-15 2025-07-24 Kalvista Pharmaceuticals Limited Methods for determining amidolytic activity

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1312564C (en) * 1985-07-12 1993-01-12 Robert W. Colman Monoclonal antibodies to human plasma prekallikrein and methods of preparing and using same
US5047323A (en) 1986-01-22 1991-09-10 Temple University Of The Commonwealth System Of Higher Education Method for detecting human kininogen using monoclonal antibodies thereto
US4908431A (en) 1986-01-22 1990-03-13 Temple University-Of The Commonwealth System Of Higher Education Monoclonal antibodies to human kininogen and methods of preparing same
US4881175A (en) 1986-09-02 1989-11-14 Genex Corporation Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
KR960009766B1 (ko) 1986-09-10 1996-07-24 니혼 소오끼 세이야꾸 가부시기가이샤 생리 활성물질 측정법
US4882272A (en) 1986-10-01 1989-11-21 Temple University - Of The Commonwealth System Of Higher Education High molecular weight kininogen assay
US5025796A (en) 1988-12-01 1991-06-25 The United States Of America As Represented By The Department Of Health And Human Services Apparatus and methods for determining in vivo response to thermal stimulation in in an unrestrained subject
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
CA2103059C (en) 1991-06-14 2005-03-22 Paul J. Carter Method for making humanized antibodies
US5472945A (en) 1991-08-13 1995-12-05 Temple University- Of The Commonwealth System Of Higher Education Modulation of blood pressure and inhibition of platelet activation with kininogen fragment
US6057287A (en) 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
ES2227545T3 (es) 1994-01-11 2005-04-01 Dyax Corporation Proteinas y sus analogos del "dominio de kunitz" inhibidores de calicreina.
JPH1084995A (ja) 1996-09-12 1998-04-07 Nippon Zoki Pharmaceut Co Ltd 血液凝固第xii因子活性化法
US5789261A (en) 1996-10-30 1998-08-04 Temple University Of The Commonwealth System Of Higher Education Solid phase immunoassay
US6242210B1 (en) 1997-05-20 2001-06-05 Actinova Limited Treatment of bacterial infections
JP4346798B2 (ja) 1999-08-19 2009-10-21 協和メデックス株式会社 Hcvコア抗原の検出または定量方法およびそれに用いる検出または定量試薬。
US6994852B1 (en) 1999-11-12 2006-02-07 Temple University-Of The Commonwealth System Of Higher Education Inhibition of angiogenesis by antibodies against high molecular weight kininogen domain 5
US7067713B2 (en) * 2000-01-31 2006-06-27 Pharming Intellectual Property B.V. C1 Inhibitor produced in the milk of transgenic non-human mammals
US7678541B2 (en) 2000-11-21 2010-03-16 Hologic, Inc. Methods and compositions for the detection of a nucleic acid using a non-invasive cleavage reaction
JP2002221519A (ja) 2001-01-29 2002-08-09 Sysmex Corp 抗凝固剤およびそれを用いた抗凝固剤処理方法
US20040152633A1 (en) 2001-05-31 2004-08-05 Jorgensen Marianne Ulrich Kunitz-type sequences and polypeptides
US6913900B2 (en) 2001-08-29 2005-07-05 Nippon Zoki Pharmaceutical Co., Ltd. Plasma prekallikrein activation and kallikrein production assay
DE60333758D1 (de) 2002-06-07 2010-09-23 Dyax Corp Prevention und Verringerung von Ischemia
AU2003281287A1 (en) 2002-07-04 2004-01-23 Oxford Glycosciences (Uk) Ltd Toxicity markers
US20070003552A1 (en) 2002-07-09 2007-01-04 Gebbink Martijn F B Cross-beta structure comprising amyloid binding proteins and methods for detection of the cross-beta structure, for modulating cross-beta structures fibril formation and for modulating cross-beta structure-mediated toxicity and method for interfering with blood coagulation
EP1598428A1 (en) * 2004-05-18 2005-11-23 Georg Dewald Methods and kits to detect Hereditary angioedema type III
JP2008515774A (ja) 2004-08-03 2008-05-15 ダイアックス コーポレイション hK1結合タンパク質
US7235530B2 (en) 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
EP1981519B1 (en) 2005-12-29 2017-12-27 Dyax Corp. Protease inhibition
US7276480B1 (en) 2005-12-30 2007-10-02 Dyax Corp. Prevention and reduction of blood loss
CA2658523C (en) 2006-07-31 2012-06-12 Activesite Pharmaceuticals, Inc. Inhibitors of plasma kallikrein
EP2089712A4 (en) 2006-11-22 2010-09-22 Life Technologies Corp BIOMARKERS OF AUTOIMMUNE DISEASES
WO2009026334A2 (en) 2007-08-21 2009-02-26 Genzyme Corporation Treatment with kallikrein inhibitors
WO2009051259A1 (ja) 2007-10-18 2009-04-23 Miyazaki Prefectural Industrial Support Foundation 肝疾患診断用バイオマーカー
US20110154517A1 (en) * 2007-10-22 2011-06-23 Georg Dewald Disorders of vasoregulation and methods of diagnosing them
KR20110057086A (ko) 2008-07-07 2011-05-31 니폰 조키 세야쿠 가부시키가이샤 섬유근 통증의 검사법
US20110212104A1 (en) 2008-11-03 2011-09-01 Schering Corporation Inflammatory bowel disease biomarkers and related methods of treatment
US20110318359A1 (en) 2008-12-02 2011-12-29 Feener Edward P Method for reducing blood pressure using inhibitors of plasma kallikrein
JP2013516389A (ja) 2009-01-06 2013-05-13 ダイアックス コーポレーション カリクレイン阻害剤による粘膜炎治療
FR2942233B1 (fr) 2009-02-19 2015-03-13 Lfb Biotechnologies Moyens pour la purification d'une proteine du plasma sanguin, et procedes pour sa mise en oeuvre
KR101077275B1 (ko) 2009-05-07 2011-10-27 한국기초과학지원연구원 당단백질의 당쇄화를 이용한 암 진단 방법
JO3244B1 (ar) 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
MX2012006913A (es) 2009-12-18 2012-08-23 Activesite Pharmaceuticals Inc Profarmacos de inhibidores de calicreina plasmatica.
US9206123B2 (en) 2009-12-18 2015-12-08 Activesite Pharmaceuticals, Inc. Prodrugs of inhibitors of plasma kallikrein
SI3459564T1 (sl) 2010-01-06 2022-06-30 Takeda Pharmaceutical Company Limited Proteini, ki vežejo plazemski kalikrein
WO2012009447A2 (en) 2010-07-13 2012-01-19 University Of Rochester THE cAMP/PKA/HDAC5 PATHWAY AND USES THEREOF
EP2645932B1 (en) 2010-12-02 2016-03-02 Becton, Dickinson and Company Blood collection devices containing blood stabilization agent
JP2014506257A (ja) * 2011-01-06 2014-03-13 ダイアックス コーポレーション 血漿カリクレイン結合タンパク質
WO2012170947A2 (en) 2011-06-10 2012-12-13 Isis Pharmaceuticals, Inc. Methods for modulating factor 12 expression
WO2012170945A2 (en) * 2011-06-10 2012-12-13 Isis Pharmaceuticals, Inc. Methods for modulating kallikrein (klkb1) expression
FR2983215B1 (fr) * 2011-11-28 2013-12-20 Univ Grenoble 1 Dosage de la capacite de controle de c1inh
EP3456744B1 (en) 2013-01-20 2023-03-29 Takeda Pharmaceutical Company Limited Evaluation and treatment of bradykinin-mediated disorders
KR20150141940A (ko) 2013-02-01 2015-12-21 벡톤 디킨슨 앤드 컴퍼니 접촉 경로를 저해하는 첨가제를 함유한 채혈 기구
AU2014340450B2 (en) 2013-10-21 2020-05-21 Takeda Pharmaceutical Company Limited Assays for determining plasma kallikrein system biomarkers
US10101344B2 (en) 2013-10-21 2018-10-16 Dyax Corp. Diagnosis and treatment of autoimmune diseases
EA038532B1 (ru) 2014-01-21 2021-09-10 Такеда Фармасьютикал Компани Лимитед Способ лечения наследственного ангионевротического отека (hae)
PL3365685T3 (pl) 2015-10-19 2021-08-02 Dyax Corp. Test immunologiczny do wykrywania rozszczepionego wielkocząsteczkowego kininogenu
AU2016372159B2 (en) 2015-12-15 2022-03-24 Takeda Pharmaceutical Company Limited Peptide quantitation assay for differentiating full-length high molecular weight kininogen (HMWK) and cleaved HMWK
WO2021154992A1 (en) 2020-01-28 2021-08-05 Orgenesis Inc. Process and system for acellular therapy

Similar Documents

Publication Publication Date Title
JP2016536012A5 (cg-RX-API-DMAC7.html)
Ouyang et al. Dysregulated serum MiRNA profile and promising biomarkers in dengue-infected patients
Hamaguchi et al. Origin of circulating free DNA in sepsis: analysis of the CLP mouse model
Xu et al. Cisplatin-induced downregulation of miR-199a-5p increases drug resistance by activating autophagy in HCC cell
Liao et al. Upregulation of FAM83D affects the proliferation and invasion of hepatocellular carcinoma
JP2016513094A5 (cg-RX-API-DMAC7.html)
JP2017503488A5 (cg-RX-API-DMAC7.html)
Ye et al. The association of renin-angiotensin system genes with the progression of hepatocellular carcinoma
WO2014140933A3 (en) Method for the prognosis and treatment of cancer metastasis
Li et al. MiR-217 is involved in the carcinogenesis of gastric cancer by down-regulating CDH1 expression
BRPI1008957B8 (pt) método para detecção simultânea de uma pluralidade de ácidos nucleicos alvo executado por um sistema de análise integrada em tempo real de ácidos nucleicos alvo
Kovalenko et al. ROS production, intracellular HSP70 levels and their relationship in human neutrophils: effects of age
JP2017500584A5 (cg-RX-API-DMAC7.html)
US10895572B2 (en) Autophagy-related nourin gene-based RNA network as early biomarkers for cardiac patients
BR112016019740A2 (pt) monitoramento do estado de inflamação
JP2017514813A5 (cg-RX-API-DMAC7.html)
JP2015523569A5 (cg-RX-API-DMAC7.html)
JP7463351B2 (ja) 脳卒中の血液バイオマーカー
CN106544342B (zh) Mt2a基因组蛋白乙酰化修饰检测试剂盒及引物对
JP2015530868A5 (cg-RX-API-DMAC7.html)
Ehrnhoefer et al. Laquinimod decreases Bax expression and reduces caspase-6 activation in neurons
Ramsay et al. Blood transcriptomic biomarker as a surrogate of ischemic brain gene expression
Solheim et al. Prothrombotic markers in patients with acute myocardial infarction and left ventricular thrombus formation treated with pci and dual antiplatelet therapy
Shen et al. Screening of differentially expressed genes related to severe sepsis induced by multiple trauma with DNA microarray.
WO2015121737A4 (en) Transcriptomic biomarkers, method for determination thereof and use of trnascriptomic biomarkers for individual risk assessment of developing post-infraction heart failure